Intensified Induction Chemotherapy with High Dose Cytarabine and Etoposide for Acute Myeloid Leukemia: A Review and Updated Results of the Australian Leukemia Study Group

References

• Priesler H., David R. B., Kirshner J., et al. Comparison of 3 remission induction regimens and two post-induction regimens for the treatment of acute non-lymphocytic leukemia. Blood 1987; 69(5)1441
   PubMed Web of Science ®Google Scholar
• Wiernik P. H., Banks P. C., Case D. C., et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adults with acute myeloid leukemia. Blood 1992; 79(2)313
   PubMed Web of Science ®Google Scholar
• Bishop J. F., Lowenthal R. M., Joshua D., et al. Etoposide in acute non-lymphocytic leukemia. Blood 1990; 75: 27
   PubMed Web of Science ®Google Scholar
• Yates J., Glidwell O., Wiernik P., et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A Calgb study. Blood 1982; 60: 454–462
   PubMed Web of Science ®Google Scholar
• Bishop J. R., Matthews J. P., Young G. A., et al. A randomised study of high dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 5
   Web of Science ®Google Scholar
• Mayer R. J., Davis R. B., Schiffer C. A., et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 3331: 896–903
   Web of Science ®Google Scholar
• Preisler H. D. Failure of remission induction in acute myelocytic leukemia. Med Pediair Oncol 1978; 4: 278
   Google Scholar
• Ellison R. R., Holland J. F., Weil M., et al. Arabinosylcytosine. A useful agent in the treatment of acute leukemia in adults. Blood. 1968; 32: 507–523
   PubMed Web of Science ®Google Scholar
• Carey R. W., Ribas-Mundo M., Ellison R. R., et al. Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia. Cancer 1975; 36: 1560–1566
   PubMed Web of Science ®Google Scholar
• Passe S., Mike V., Mertelsmann R., et al. Acute non-lymphoblastic leukemia. Prognostic factors in adults with long-term follow up. Cancer 1982; 50: 1462–1471
   PubMed Web of Science ®Google Scholar
• Gale R. P., Cline M. S. High remission induction rate in acute myeloid leukaemia. Lancet 1977; 1: 497–499
   PubMed Web of Science ®Google Scholar
• Mandelli F., De Lipsis E., Grignani F., et al. Daunomycin, cytosine arabinoside and thioguanine (DAT) vs vincristine, cytosine arabinsode, and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocytic leukemia: a randomized collaborative study. Med Pediatr Oncol 1978; 4: 231–240
   PubMedGoogle Scholar
• Wiernik P. H., Glidwell O. J., Hoagland H. C., et al. A comparative trial of daunorubicin, cytosine arabinoside and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia. Med Pediatr Oncol 1979; 6: 261–277
   PubMedGoogle Scholar
• Mayer R. J. Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. 5pm. Oncol 1987; 14(4)384–396
   Google Scholar
• Omura G. A., Vogler W. R., Lefante J., et al. Treatment of acute myelogenous leukemia: Influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy. Cancer 1982; 49: 1530–1536
   PubMedGoogle Scholar
• Preisler H., David R. B., Krishner J., et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute non-lymphocytic leukemia: A Cancer and Leukemia Group B Study. Blood 1987; 69: 1441–1449
   PubMed Web of Science ®Google Scholar
• Bishop J. F. The treatment of adult acute myeloid leukemia. Semin Oncol 1997; 22(1)57–69
   Google Scholar
• Rai K. R., Holland J. F., Glidewell O. J., et al. Treatment of acute myelocytic leukemia: A study by Cancer and Leukemia Group B. Blood 1981; 58: 1203–1212
   PubMed Web of Science ®Google Scholar
• Sauter C., Berchtold W., Foopp M., et al. Acute myelogenous leukaemia: Maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet 1984; 1: 379–382
   PubMed Web of Science ®Google Scholar
• Vogler W. R., Winton E. F., Gordon D. S., et al. A randomised comparison of post remission therapy in acute myelogenous leukemia: A Southeastern Cancer Study Group trial. Blood 1984; 63: 1039–1045
   PubMed Web of Science ®Google Scholar
• Dillman R. O., Davis R. B., Green M. R., et al. Comparison of ara-C at 200 mg/m2 and 100 mg/nr in induction and maintenance therapy for acute myelocytic leukemia (AML). ProcAm Soc Clin Oncol 1987; 6: 160, (abst 629)
   Google Scholar
• Rees J. K. H., Gray R. G., Swinskey D., et al. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; 2: 1236–1241
   PubMed Web of Science ®Google Scholar
• Buchner T., Hiddemann W., Schaefer U. W., et al. Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML. Leukemia 1992; 6(Suppl 4)68–70
   Google Scholar
• Legha S. S., Keating M. J., Zander A. R., et al. 41 (9-acridinylamino methansesulphon-m-aniside (Amsa): a new effective drug in the treatment of adult acute leukemia. Ann Intern Med 1980; 93: 17
   PubMed Web of Science ®Google Scholar
• Louie A. C., Issell B. F. Amsacrine (AMSA) - a clinical review. J Clin Oncol 1985; 3: 562
   PubMed Web of Science ®Google Scholar
• Paciucci P. A., Ohnuma T., Cuttner J., et al. Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 1983; 43: 3919
   PubMed Web of Science ®Google Scholar
• Estey E. H., Keating M. J., McCredie ???, et al. Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 1983; 67: 389
   PubMedGoogle Scholar
• Daghestani A., Arlin Z. A., Leyland-Jones B., et al. Phase I and II clinical and pharmacological study of 4-methoxy daunorubicin (idarubicin) in adult patients with acute leukemia. Cancer Res. 1985; 45: 1408
   PubMed Web of Science ®Google Scholar
• Carella A. M., Santini G., Martinengo M., et al. 4-demethoxydaunorubicin (idarubicin) in refractory or relapsed acute leukemia. Cancer 1985; 55: 1452
   PubMed Web of Science ®Google Scholar
• Clarkson B. D., Gee T., Mertelsmann R., et al. Current status of treatment of acute leukemia in adults. An overview of the Memorial experience and review of the literature. Crit Rev Oncol/Hematol 1986; 4: 221–248
   PubMed Web of Science ®Google Scholar
• Arlin Z. A., Case D. C., Jr., Moore J., et al. Randomised multicentre trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute non-lymphocytic leukemia (Anll). Leukemia 1990; 4: 177
   PubMed Web of Science ®Google Scholar
• Martial P., Ghilian J. M., Ferrant A., et al. High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukemia. Eur J Haematol 1990; 45(3)164–7
   PubMed Web of Science ®Google Scholar
• Stuart-Harris R., Simes J., Coates A. S., et al. Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantrone. Eur J Cancer Clin Oncol 1987; 23: 557–561
   PubMedGoogle Scholar
• Supino A., Necca A., Dasidia J., et al. Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin. Cancer Res 1977; 37: 4523
   PubMed Web of Science ®Google Scholar
• Speth P. A. J., Van de Loo F. A. J., Linssen P. C. M., et al. Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin. Clin Pharmacol Ther 1986; 40: 643
   PubMed Web of Science ®Google Scholar
• Gillies H. C., Herriot D., Liang R., et al. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin IMI-30, NSC 256439) following intravenous and oral administration in patients with advanced cancer. Br J Clin Pharmacol 1987; 28: 303
   Google Scholar
• Hayat M., Hurteloup P., Parmeutier C., et al. Phase I trial of idarubicin (4-demethoxydaunorubicin) in adult acute myeloid leukemia. Invest New Drugs 1984; 2: 375
   PubMed Web of Science ®Google Scholar
• Harousseau J. L., Hurtleoup P., Reiffers J., et al. Idarubicin in the treatment of acute leukemia. Exerpta Medica Pub., AmsterdamThe Netherlands 1987; 10
   Google Scholar
• Berman E., Heller G., Santorsa J., et al. Results of a randomised trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinsode in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77(8)1666–1674
   PubMed Web of Science ®Google Scholar
• Vogler W. R., Velez-Garcia E., Omura G., et al. A phase 3 trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia. J. Clin Oncol 1992; 10(7)1103–11
   PubMed Web of Science ®Google Scholar
• Petti M. C., Mandelli F. Idarubicin in acute leukemias: Experience of the Italian Cooperative Group Gimema. Semin Oncol 1989; 16(1)10–15, Suppl 2
   PubMed Web of Science ®Google Scholar
• Wheatley K. Meta-analysis of randomised trials of idarubicin (IDAR) or mitoxantrone (MITO) vs daunorubicin as induction therapy for acute myeloid leukemia (AML). Blood 1995; 86(10)434a
   Google Scholar
• Leike J. VP16–213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity. Cancer Chemother Pharmacol 1982; 7: 103
   PubMed Web of Science ®Google Scholar
• Rivera G., Avery T., Roberts D. Response to L1210 to combination of cytosine arabinoside and VM26 or VP16–213. Eur J Cancer 1975; 11: 639
   PubMed Web of Science ®Google Scholar
• Bishop J. F. Etoposide in the management of acute leukemia: A review. Semin Oncol 1991; 18(Suppl 2)62–69
   PubMedGoogle Scholar
• Van Echo D. A., Lichenfeld K. M., Wiemik P. H. Vinblastine, 5 azacytidine and VP16–213 therapy for previously treated patients with acute non-lymphocytic leukemia. Cancer Treat Rep 1977; 61: 1599
   PubMedGoogle Scholar
• Dubowski D., Kemoff L., Jacobs P. Rapid remission induction in adult acute non-lymphocytic leukemia. Eur J Cancer 1978; 14: 1177
   Web of Science ®Google Scholar
• Letandre L., Hinemann V., Hoagland C. H., et al. Phase 1 trial of VP16 and Amsa in combination in patients with refractory acute non-lymphocytic leukemia. Proc Amer Soc Clin Oncol 1984; 3: 189
   Google Scholar
• Bishop J. F., Joshua D. E., Lowenthal R. M., et al. A Phase I–II trial of cytosine arabinoside, daunorubicin and VP16–213 in adult patients with acute non-lymphocytic leukemia. Aust NZ J Med 1986; 16: 48
   PubMedGoogle Scholar
• Parkiha P., Powles R., Treleaven J., et al. High dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukemia: a single centre study. Br J Cancer 1990; 62(5)830–3
   PubMed Web of Science ®Google Scholar
• Lowenthal R. M., Matthews J. P., Bishop J. F., et al. Idarubicin, cytosine arabinoside in standard or high dose, and etoposide: combinations giving high remission rates in adult acute myeloid leukemia (AML). Blood 1993; 82: 328a, (abstract)
   PubMed Web of Science ®Google Scholar
• Vogler W. R., McCarley D. H., Stagg M., et al. A Phase III trial of high dose cytosine arabinsode with or without etoposide in relapsed and refractory acute myelogenous leukemia. Leukemia 1994; 9(11)1847–53
   Google Scholar
• Burnett A. K., Goldstone A. H., Stevens R., et al. The value of bone marrow transplantation in AML CR1 in intensively treated patients. The MRC AML 10 trial. Ann Hematol 1995; 70(Suppl 1)A112
   Google Scholar
• Slevin M. L., Clark P. I., Joel S. P., et al. A randomised trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989; 7(9)1333, 40
   PubMed Web of Science ®Google Scholar
• Plunkett W., Iacoboni S., Keating M. J. Cellular pharmacology and optimal therapeutic concentrations of 1-sZ-D arabinofuranosylcytosine 5′—triphosphate in leukemic blasts during treatment of refactory leukemia with high dose 1-sZ-D arabinofuranosylcytosine. Scand J Haematol 1986; 44: 51–59
   Google Scholar
• Rustum Y. M., Preisler H. D. Correlation between leukemic cell retention of 1-B-D-arabinofuranosyl-cytosine 51–triphosphate and response to therapy. Cancer Res 1979; 39: 42–49
   PubMed Web of Science ®Google Scholar
• Hines J. D., Oken M. M., Mazza J., et al. High dose cytarabine and m-AMSA is effective therapy in relapse acute non-lymphocytic leukemia. J Clin Oncol 1984; 2(suppl 1)545–549
   PubMedGoogle Scholar
• Champlin R., Ho W., Winston D., et al. Treatment of adults with acute myelogenous leukemia: prospective evaluation of high dose cytarabine in consolidation chemotherapy and with bone marrow transplantation. Semin Oncol 1987; 14: 1–6
   PubMed Web of Science ®Google Scholar
• Mayer R. J., Schiffer C. A., Peterson B. A., et al. Intensive post-remission therapy in adults with acute non-lymphocytic leukemia using various dose schedules of ara-C: a progress report from CALGB. Semin Oncol 1987; 14(2 suppl 1)25–31
   PubMed Web of Science ®Google Scholar
• Brito-Babapulle F., Catovsky D., Newland A. C., et al. Treatment of acute myeloid leukemia with intermediate dose cytarabine and mitoxantrone. Semin Oncol 1987; 14(2 supp 1)51–52
   PubMed Web of Science ®Google Scholar
• Bishop J. F., Matthews J. P., Young G. A., et al. The influence of induction chemotherapy dose and dose intensity on the duration of remission in acute myeloid leukaemia. Leukaemia and Lymphoma 1994; 15: 79–84
   PubMed Web of Science ®Google Scholar
• Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281–1288
   PubMed Web of Science ®Google Scholar
• Williams S. D., Birch R., Einhorn L. H., et al. Treatment of disseminated germ cell tumours with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435–40
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Gaynor E., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Engl J Med 1993; 328: 1002–6
   PubMed Web of Science ®Google Scholar
• Rubin E. H., Anderson J. W., Berg D. T., et al. Risk factors for high dose cytarabine neurotoxicity: an analysis of a Cancer and Leukemia Group B trial in patients with acute myeloid leukemia. J Clin Oncol 1992; 10(6)948–53
   PubMed Web of Science ®Google Scholar
• Weick J. K., Kopecky K. J., Appelbaum F. R., et al. A randomised investigation of high dose versus standard dose cytoside arabinoside with daunorubicin in patients with previously untreated acute myelogenous leukemia. Blood 1996; 88: 2841–2851
   PubMed Web of Science ®Google Scholar
• Plunkett W., Liliemark J. O., Estey E., et al. Saturation of ara-CTP accumulation during high-dose ara-C therapy: Pharmacologic rationale for intermediate-dose ara-C. Semin Oncol 1987; 14(2 Suppl 1)159–166
   PubMed Web of Science ®Google Scholar
• Mayer R. J., Weinstein H. J., Coral F. S., et al. The role of intensive post induction chemotherapy in the management of patients with acute myelogenous leukemia. Cancer Treat Rep 1982; 66: 1455–1462
   PubMedGoogle Scholar
• Embury S. H., Elias L., Heller P. H., et al. Remission maintenance therapy in acute myelogenous leukemia. West J Med 1977; 126: 267–272
   PubMedGoogle Scholar
• Cassileth P., Harrington D., Hines J., et al. Maintenance therapy in adult acute nonlymphocytic leukemia (Anll) prolongs initial complete remission duration (Crdur). Blood 1986; 68(suppl 1)220a, abstrc 758
   PubMed Web of Science ®Google Scholar
• Cassileth P. A., Begg C. B., Bennett J. M., et al. A randomised study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood 1984; 63: 843–847
   PubMed Web of Science ®Google Scholar
• Dutcher J. P., Wiemik P. H., Markus S., et al. Intensive maintenance therapy improves survival in adult acute non-lymphocytic leukemia: an eight year follow up. Leukemia 1988; 7: 413
   Google Scholar
• Casseleith P. A., Begg C. B., Silber R., et al. Prolonged unmaintained remission after intensive consolidation therapy in adult acute non-lymphocytic leukemia. Cancer Treat Rep 1987; 71: 137
   PubMedGoogle Scholar
• Preisler H. D., Raza A., Early A., et al. Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J Clin Oncol 1987; 5: 722–30
   PubMed Web of Science ®Google Scholar
• Tricot G., Boogaerts M. A., Vlientink R., et al. The role of intensive remission induction and consolidation treatment in patients with acute myeloid leukemia. Brit J Haematol 1987; 66: 37–44
   PubMed Web of Science ®Google Scholar
• Wolff S. N., Herzig R. H., Fay J. W., et al. High dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long term follow up and results. J Clin Oncol 1989; 7: 1260–7
   PubMed Web of Science ®Google Scholar
• Schiller G., Gajewski J., Territo M., et al. Long term outcome of high dose cytarabine based consolidation therapy for adults with acute myelogenous leukemia. Blood 1992; 80: 2977–82
   PubMed Web of Science ®Google Scholar
• Cassileth P. A., Lynch E., Hines J. D., et al. Varying intensity of post-remission therapy in acute myeloid leukemia. Blood 1992; 79(8)1924–1930
   PubMed Web of Science ®Google Scholar
• Lowenthal R. M., Bradstock K. M., Matthews J. P., et al. Idarubicin, cytarabine in standard dose or high dose and etoposide ± lenograstim (G-CSF) for adult acute lyeloid leukaemia (AML). Blood 1995; 86(10)768a, (abstract)
   Google Scholar
• Clift R. A., Buckner C. D., Thomas E. D., et al. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2: 243–248
   PubMed Web of Science ®Google Scholar
• Bishop J. F. Intensified therapy for acute myeloid leukemia. N Engl J Med 1994; 331: 941–942, (editorial)
   PubMed Web of Science ®Google Scholar
• Bishop J. F., Matthews J. P., Young G. A. R., Bradstock K. M. Factors associated with poor outcome following induction therapy for acute myeloid leukemia. Int J Hematol 1996; 64(suppl 1)S19
   Google Scholar